MedPath

FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors

10 months ago3 min read

Key Insights

  • The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment.

  • Cobenfy targets muscarinic receptors, unlike traditional antipsychotics that focus on dopamine, potentially reducing side effects like weight gain and movement disorders.

  • Clinical trials demonstrated Cobenfy significantly reduced schizophrenia symptoms compared to placebo, marking a transformative moment in managing this challenging condition.

The FDA has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, representing the first new class of drug for this condition in over three decades. This oral agent offers a novel approach by targeting M1 and M4 muscarinic receptors, differing from traditional antipsychotics that primarily affect dopaminergic and serotonergic pathways. The approval provides a new alternative for patients who may not respond to or tolerate dopamine-blocking agents. Tiffany Farchione, MD, of the FDA's Center for Drug Evaluation and Research, stated that this drug takes the first new approach to schizophrenia treatment in decades, offering a new option for managing this challenging condition.

Efficacy and Safety Data

The approval of Cobenfy was supported by data from the EMERGENT clinical program, including the EMERGENT-2 and EMERGENT-3 trials. These 5-week trials demonstrated statistically significant reductions in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (P < 0.0001 for both):
  • EMERGENT-2: -21.2 vs -11.6, respectively
  • EMERGENT-3: -20.6 vs -12.2, respectively
Key secondary endpoints were also met in EMERGENT-2. Rishi Kakar, MD, of Segal Trials, highlighted that Cobenfy offers a new option by leveraging a novel pathway, addressing the heterogeneous nature of schizophrenia.

Side Effects and Contraindications

The most common side effects of xanomeline-trospium chloride (in ≥5% of patients and at least twice placebo) included nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, and gastrointestinal reflux disease. The combination was not associated with side effects typically common of other schizophrenia agents, such as weight gain, somnolence, and extrapyramidal symptoms. Contraindications include urinary retention, moderate or severe hepatic impairment, gastric retention, a history of hypersensitivity to the ingredients, or untreated narrow-angle glaucoma. Warnings address angioedema, central nervous system effects, increased heart rate, and use in patients with biliary disease. It is not recommended in patients with moderate to severe renal impairment (eGFR <60 mL/min/1.73 m2).

Dosing and Availability

Xanomeline-trospium is available in 50 mg/20 mg, 100 mg/20 mg, and 125 mg/30 mg capsules. Bristol Myers Squibb anticipates launching the drug in late October, with an expected list price of $1,850 per month or approximately $22,500 annually before rebates or discounts.

Market Impact and Analyst Projections

Analysts project that Cobenfy could reach peak sales of $2.4 billion for schizophrenia and an additional $3.9 billion for Alzheimer's psychosis. BMO Capital adjusted its price target on Bristol-Myers Squibb shares to $53.00, while Goldman Sachs reaffirmed a Buy rating with a price target of $57.00. The FDA approval also triggers $29 million in payments to PureTech, the original developer of the drug, with potential future royalties on net annual sales over $2 billion.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Clinical Trials

Related research and studies

Highlighted Clinical Trials

NCT06027086RecruitingPhase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Posted 2/12/2024

Related News

Sources

BMS wins approval for schizophrenia drug acquired from Karuna

pharmaceutical-technology.comSep 27, 2024

FDA Approves Cobenfy - Exponent

uwpexponent.comOct 10, 2024

Cobenfy approval | Pharmacy Daily

pharmacydaily.com.auSep 30, 2024

Bristol Myers' schizophrenia drug fails key study

beckershospitalreview.comApr 23, 2025
© Copyright 2025. All Rights Reserved by MedPath